CRISPR Therapeutics raises $64 mln
CRISPR Therapeutics said Wednesday it raised $64 million in financing, including $35 million in a Series A and $29 million in a Series B. Strategic investors, SR One and Celgene Corp., led the rounds while new investors New Enterprise Associates and Abingworth, alongside the Company’s founding investor, Versant Ventures, also participated. CRISPR Therapeutics, of Basel, Switzerland, is a biopharmaceutical company.
29 April 2015•4 mins read
